Active

Epidarex Capital

Investor type

VC / PE

Founded

2010

AUM

$395 M

Location

Bethesda, Maryland, United States

Investment Ticket

$50-100 m

Investment Stage

Series A Seed Late Stage (Series C+)

Region of investment

North America Europe
Investor profile last updated: 09 April, 2026

Profile

Epidarex Capital is a leading transatlantic venture capital firm that invests in early-stage, high growth life science opportunities in under-ventured markets. Epidarex funds ground-breaking research, often building companies from scratch, to address large unmet medical needs with solutions that provide significant benefits to patients.

Industry

Biotechnology Fintech Healthcare Services Medical Devices Pharmaceuticals Financial Services MedTech Technology Life Sciences Infrastructure HealthTech

Epidarex Capital Funds

Name Type
Questionare
Industry
Questionare
Stage
Questionare
Region
Size AUM Launch date
Epidarex Capital II
Venture Capital (VC)
Financial Services
Fintech
Healthcare Services
HealthTech
Pre-seed
Seed
North America
Europe
$5-10 m
$47 M
May 2014
Epidarex Capital III
Venture Capital (VC)
Financial Services
Fintech
Healthcare Services
HealthTech
Pre-seed
Seed
North America
$5-10 m
$105 M
June 2020
Epidarex Capital IV
Venture Capital (VC)
Financial Services
Fintech
Healthcare Services
HealthTech
Pre-seed
Seed
North America
$5-10 m
$110 M
January 2026

Contacts

Name
Title
Email
avatar
Elizabeth Roper Partner
Partner
-
avatar
Kyparissia Sirinakis Managing Partner
Managing Partner
-
Upgrade to see contacts
avatar
OA34Q7RmYV9fygGE OA34Q7RmYV9fygGE
OA34Q7RmYV9fygGE
avatar
OA34Q7RmYV9fygGE OA34Q7RmYV9fygGE
OA34Q7RmYV9fygGE
avatar
OA34Q7RmYV9fygGE OA34Q7RmYV9fygGE
OA34Q7RmYV9fygGE
Investment-team contacts for Epidarex Capital — including verified work emails and LinkedIn profiles — are available to Private Equity List subscribers.
Instant access on the web. Plans from $129/month — see pricing.
Contacts sourced from the firm's website and LinkedIn, re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.

FAQs about Epidarex Capital

Epidarex Capital is a venture capital and private equity firm. It backs companies at Series A, Seed and Late Stage (Series C+), writing tickets of $50-100 m.
Epidarex Capital is located in Bethesda, Maryland, United States.
Epidarex Capital was founded in 2010.
Epidarex Capital invests in companies and startups in Biotechnology, Fintech, Healthcare Services, Medical Devices, Pharmaceuticals, Financial Services, MedTech, Technology, Life Sciences, Infrastructure, HealthTech.
Epidarex Capital invests in companies and startups in North America, Europe.
Epidarex Capital invests in companies and startups at Series A, Seed, Late Stage (Series C+).
Epidarex Capital usually invests $50-100 m on average.
Epidarex Capital has around $395m assets under management.
Epidarex Capital last fund was created/launched in 2026-01-27
Epidarex Capital can be reached through its website epidarex.com, its LinkedIn page and its X account. Its general enquiries address is info@epidarex.com. Cold-mailing a general inbox rarely reaches a partner, so Private Equity List also lists the investment-team contacts for Epidarex Capital — names, roles, verified work emails and LinkedIn profiles — available on a Pro plan from $129/month (see pricing). Contacts are sourced from the firm's website and LinkedIn and re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.
Yes. Every field on this page — profile, funds, investment criteria, portfolio and investment-team contacts — is available programmatically through the Private Equity List REST API and MCP server, so AI assistants such as Claude and ChatGPT can query Epidarex Capital directly instead of scraping this page. One subscription covers both the web app and machine access — see API & MCP.
Private Equity List re-verifies investor profiles on a rolling cycle, pulling from the firm's own website and LinkedIn rather than a one-off import. This profile was last updated on 09 April, 2026. Something out of date here? Report it — we re-run that firm within 48h and get back to you.